Abstract Several lines of evidence suggest that neuroimmune mechanisms may be involved in the neurodegenerative process of Parkinson's disease (PD). Interleukin-6 (IL-6) is increased in the nigrostriatal region and in the cerebrospinal fluid of patients with PD. IL-6 serum level was evaluated in PD patients. The effects of levodopa treatment and disease severity on IL-6 were also studied. The IL-6 levels were similar between PD patients (treated and not treated) and controls. However, there was a negative correlation of IL-6 levels and the activities of daily living scale (P \ 0.05), indicating that patients with more severe disease have higher levels of this cytokine. No correlation involving levodopa treatment and IL-6 serum level was found. The results suggest that only marginal effects of IL-6 occur on the peripheral immune system, and that the role of IL-6 and others neuroimmune factors needs to be well elucidated on PD.
Introduction
Parkinson's disease (PD) is a common neurodegenerative disorder characterized mainly by resting tremor, slowness of movement, rigidity, and postural instability. The etiology of this disorder is still unknown, although many different hypotheses have been studied. The causes are likely to be multiple and to involve not only single factors acting alone (e.g., gene mutations), but also several factors acting together [1] . Several lines of evidence have pointed that neuroimmune mechanisms may be involved in the neurodegenerative process of PD [2, 3] .
It is well known that the immune system in the brain plays a critical role under brian injuries and neuronal death [2] . Any kind of brain damage (including the idiopathic injury caused by PD) is followed by a glial cell protective response [4] . In the brain of PD patients there is a consistent higher density of activated glial cells in the substantia nigra compared to other midbrain areas and other brain regions. Beside the protective role of this response, some authors suggest that it seems to be neuroprotective only at early stages of PD and it may become neurotoxic during the progression of the disease [4] [5] [6] .
Proinflammatory cytokines, such as tumor necrosis factor alpha (TNFa), interleukin 1 (IL-1) and interleukin 6 (IL-6) have been pointed as capable to induce neuronal death in some of the neurodegenerative disorders, including Parkinson's disease [5] [6] [7] . These cytokines increase leukocyte adhesion and migration, disrupt the blood-brain barrier and induce glial cell activation. This could subsequently lead to the overproduction of reactive oxygen species and to the induction of apoptosis and specific cytolysis caused by the activation of the complement system [5, 7] . It is important to realize that proinflammatory cytokines in brain are not only secreted by glial cells, but also by neurons.
IL-6, a member of the neuropoietic cytokine family, plays an essential role in development, differentiation, degeneration and regeneration of neurons in the central and peripheral nervous system and can stimulate glial cells [8, 9] . IL-6 is also involved in the synthesis of acute phase proteins and enhances survival of catecholaminergic and cholinergic neurons. Its actions are manifested in an opposite fashion, either supporting cell survival or inducing cell death [9] .
Several studies investigated the function of cytokines in the neuropathology of PD however, the specific role of IL-6, in this context, is not well established. Concentration of IL-6 increases in nigrostriatal region of postmortem brain and in cerebrospinal fluid (CSF) of PD patients and its levels in CSF inversely correlates with the severity of PD [10] [11] [12] [13] . Some studies have shown no difference in plasmatic levels of IL-6 [12, 14] , while others found elevated levels in PD patients with severe depression [15] . One paper reported that IL-6 was at higher plasmatic levels in patients with a rapidly progressing disease when compared to patients with usual progression [15] . It was also reported that levodopa, in physiological concentrations, presented an immunomodulatory effect on cells from both PD patients and controls and caused a stimulation of IL-6 production [16] .
In the present work, our primary objective is to study IL-6 serum levels in patients with PD treated and nontreated with levodopa and in controls subjects. We also aim to assess if there is any correlation between IL-6 serum levels and some clinical features of PD.
Experimental Procedure

Patients and Controls
Blood samples were obtained from PD patients receiving levodopa (n = 23) attending the Movement Disorders Clinics of the Hospital de Clı´nicas de Porto Alegre and from PD patients naive of therapy (n = 17) through external communication (newspaper). Inclusion criteria were patients with PD fulfilling the UK Parkinson's Disease Society Brain Bank clinical diagnostic criteria [17] . Subjects with metabolic disturbances, other neurological diseases or with inflammatory or infectious disorders were excluded. The clinical stage of PD was evaluated according to the classification of Hoehn and Yahr (HY) [18] and the Schwab and England activities of daily living (ADL) scale [19] . Patients that had been recently diagnosed were followed after treatment and were excluded when a good response to antiparkinsonian drugs was not achieved. The approval from local Ethics Committee was obtained and written consent was provided by all subjects.
A similar age and sex group (n = 23) was examined and blood samples were collected from a community approach (relatives of the patients without blood relations), which was defined as the control group of study. All people from this group were healthy and showed no parkinsonian signs or other neurological disorders.
Interleukin-6
Blood samples (5 ml) from patients and controls were collected without anticoagulant and sera were frozen at -70°C until analyzed. The Biotrak TM human (h) IL-6 ELISA system from Amersham Biosciences was used for measuring IL-6 in serum of all patients and controls. The optical density was determined at 450 nm.
Statistical Analysis
Comparison between groups was performed by t-test for time of disease (only the two PD groups were compared for this variable), Chi-square test for gender, one-way analysis of variance (ANOVA) followed by post hoc of Tukey for age and IL-6 levels and Mann-Whitney test for HY and ADL scales (only between PD groups). Correlations are presented with Pearson's coefficient. Statistical significance was considered as P \ 0.05.
Results
Clinical and demographical characteristics of patients and controls are depicted in Table 1 . There was no statistically significant difference between PD patients treated and not treated concerning of first symptom, predominant symptom and HY and ADL scales. There was a difference in the time of disease between PD patients treated and not treated, being almost three times lower in the later group (P = 0.002).
We found similar IL-6 serum concentrations between groups (Table 1 ). In the group with levodopa therapy, serum IL-6 presented a negative correlation with ADL scale (Fig. 1) , which decreases with the severity of PD (n = 23, r = -0.457, P \ 0.05). However, there were no associations between IL-6 levels and time of disease, HY scale and levodopa dosage (data not shown). Furthermore, time of disease correlated with HY scale (r = 0.485, P \ 0.02), but not with ADL scale.
Discussion
Abnormal immune functions have been postulated to be one of the mechanisms underlying the pathogenesis of PD. This neuroimmune hypothesis comes from evidences of alterations in glial cells and in cytokines production in the brain of patients with PD [3, 4] . As a member of proinflammatory cytokines, IL-6 is known to play a key role in this interaction between nervous and immune system [8] .
Although glial cells may be involved in the pathophysiology of several degenerative diseases, they have been poorly studied in PD. Recent evidence supports the possibility that glial cells secrete factors that have either protective or deleterious effects on dopaminergic neurons [20] . Signals that activate microglia [21, 22] and astrocytes [22] [23] [24] [25] [26] such as neurotransmitters (e.g., noradrenaline, histamine, substance P) and inflammatory mediators trigger IL-6 synthesis and release it.
Proinflammatory cytokines such as IL-1b, and TNF-a are potent stimulators of neuronal IL-6 synthesis [4] . The fact that IL-6 synthesis in brain may be induced by proinflammatory cytokines and neurotransmitters/neuropeptides supports the concept of a tight cross-communication between neurons and glial cells. This may be of significance not only for maintaining brain homeostasis and neuronal differentiation, but also for pathological processes occurring during central nervous system (CNS) neurodegeneration [9] .
Our study did not detect any significant difference in IL-6 serum levels in PD patients when compared to control individuals, which is in agree with previous reports of IL-6 plasmatic levels [12, 14] . Despite these negative findings, elevated IL-6 levels in the CSF and in nigrostriatal dopaminergic region of PD patients were well documented [10] [11] [12] [13] .
There is some evidence pointing that levodopa can act as a neuroimmune modulator in PD patients [16] . One study found that peripheral mononuclear cells from patients with PD had an enhanced production of IL-6 when compared to control cells and that an in vitro treatment with levodopa was capable to increase furthermore the production of this cytokine only in the cells from patients with PD [16] . In the present study, we found no alterations in IL-6 levels comparing PD patients treated with levodopa and not treated. Moreover, correlations between levodopa dosage and IL-6 levels were not found. There are studies that evaluated IL-6 in PD patients with and without treatment, but as far as we know, this is the first study that compared IL-6 levels of PD patients between these two groups.
Interestingly, we found an inverse correlation between serum IL-6 levels in PD patients treated with levodopa and ADL scale, indicating that a more severe clinical picture is associated with increased levels of IL-6. In agreement with our finding is the information that patients with a rapidly progressing disease, and thus a more severe clinical presentation, have higher IL-6 plasmatic levels than PD patients with a normal evolution [15] . Previous studies depicted that IL-6 plasmatic levels of PD patients were normal, while CSF concentration of this cytokine in PD patients without treatment was inversely correlated with severity of disease [12, 13] . These findings on CSF of PD patients are in contrast to what we found for serum IL-6 levels. However, we should not forget that there are important differences considering peripheral and CNS immune system. Many mechanisms could be responsible for this direct correlation between serum levels of IL-6 and severity of disease. One of these possibilities could be due to neuronal damage, and thus cytokine liberation, in other brain regions, which is known to occur during the progression of PD [27] . Another possible explanation could be the longer time of treatment in these patients with severe disease however, this seems not to be true, since we showed no correlations between IL-6 levels and time of diseasewhich is related to a longer time of treatment. Further studies are necessary to clarify this question.
We should also consider that we found no correlations between IL-6 levels and Hoehn Yahr scale. This difference between ADL and Hoehn Yahr scales could happen because these instruments evaluate different parameters of PD.
In summary, our study suggests only marginal effects on IL-6 peripheral levels of PD patients, which were related to a more severe clinical picture. We should consider that a clear IL-6 neuroimmune dysfunction was only described in post mortem brain and in CSF of PD patients, and thus being mainly related to the CNS. Proinflammatory cytokines have a great variety of roles in neurodegenerative disorders and their effects seem to be made by complex and interacting biological pathways rather than a simple direct mechanism.
